Australia's Monash University has announced the establishment of the Monash Boston Hub located in Boston, US. The Hub is dedicated to deepening collaborations with North America and Europe to fast-track drug discovery and health innovations with the goal to ultimately deliver potential new life-changing pathways for patients in Australia and around the world.
In the last five years, Monash has completed more than 160 new license deals and created 30-plus spinout companies, which together have raised over A$1.5 billion in investment.
Importantly, many of these commercial successes have been the driving force behind getting much-needed new treatment options a step closer to tackling a broad range of major global health challenges including depression, schizophrenia, cancers, fibrotic diseases, cardiovascular diseases and more.
While the Hub is strongly focused on drug discovery and health innovation, it will also serve as a launchpad for commercial opportunities across a wide range of fields including engineering, advanced materials, and energy.
The Monash Boston Hub is located in the Cambridge Innovation Centre and will include a team of development professionals headed by Boston native Nathan Elia, Monash’s Director of Enterprise for North America and Europe.
